Insight Molecular Diagnostics (IMDX) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Insight Molecular Diagnostics (IMDX) has outperformed Anbio Biotechnology (NNNN) over the past year, losing 6.0% versus a loss of 83.4%. Anbio Biotechnology is the larger company by market cap ($203.0 million vs $105.4 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMDX | NNNN |
|---|---|---|
| Share price | $3.22 | $4.63 |
| Market cap | $105.37M | $203.00M |
| 1-day change | -6.95% | -5.61% |
| YTD return | -53.87% | -83.70% |
| 1-year return | -5.98% | -83.37% |
| 5-year return | -94.91% | — |
| P/E ratio (TTM) | — | 30.83 |
| EPS (TTM) | $-1.52 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.51 | $44.73 |
| 52-week low | $2.42 | $4.56 |
| Distance from 52-week high | -62.16% | -89.66% |
| Average volume | 233.13K | 147.21K |
| Shares outstanding | 32.72M | 43.89M |
| Employees | — | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMDX has outperformed NNNN by 77.4 percentage points over the past year.
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
IMDX vs NNNN FAQ
Which is bigger, Insight Molecular Diagnostics or Anbio Biotechnology?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $203.00M compared with $105.37M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, IMDX or NNNN?
IMDX returned -5.98% over the past 12 months, compared with -83.37% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Insight Molecular Diagnostics and Anbio Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.